PROGRAM CHAIR
Martina J. Porter, MD
Dermatologist
Beth Israel Deaconess Medical Center
Harvard Medical Faculty Physicians (HMFP)
Boston, Massachusetts
PROGRAM OVERVIEW
This activity provides an overview of the evolving landscape of hidradenitis suppurativa (HS), including the rationale for current and emerging targeted treatment options and the supporting clinical evidence for patients with moderate-to-severe disease. In addition, the importance of screening and early diagnosis of HS will be highlighted as a key strategy for initiating targeted therapies earlier, thereby optimizing clinical outcomes and delivering more effective patient-centered care.
TARGET AUDIENCE
This activity is designed to meet the educational needs of dermatologists, dermatology nurse practitioners, and dermatology physician assistants involved in the management of patients with HS.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Review the mechanisms underlying the pathophysiology of HS, including the rationale for targeted therapies
- Apply evidence-based strategies for screening and diagnosing HS in a timely manner, including comorbidities associated with HS
- Combine the latest clinical evidence of targeted therapies into patient-centered treatment plans for patients with HS
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
AAPA CREDIT DESIGNATION STATEMENT – ENDURING MATERIALS
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until 8/17/2027. PAs should only claim credit commensurate with the extent of their participation.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Martina J. Porter, MD | Consultant and investigator for: AbbVie, Avalo Therapeutics, Arcutis Biotherapeutics, Aristea Therapeutics, Eli Lilly and Company, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Regeneron, Sanofi, Sonoma Biotherapeutics, Takeda, UCB, Zura Bio. Consultant for: Almiral, Corvus, FIDE, Insmed, Oruka, Otsuka, Propeller Biosciences, Spyre, Trifecta Clinical/WCG. Investigator for: AnaptysBio, Bayer, Bristol Myers Squibb, OASIS Pharmaceuticals, and Ventyx. Fellowship funding to institution: AbbVie. Royalties: Beth Israel Deaconess Medical Center. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- A medical reviewer from CE Peer Review LLC, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: August 17, 2026
EXPIRATION DATE: August 17, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
